Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose ...
Medicenna Therapeutics Corp.: Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression aft ...
MarTech on MSN10h
4 tips for helping your email marketing team stay organized
Organization is the unsung hero of email marketing success, and it's especially important during the busiest times of the ...
precisionmedicineonline7h
EMA's CHMP Recommends Approval for First-Line Opdivo-Yervoy in Certain Colorectal Cancers
Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.
Floor14h
MSI Opens New Minneapolis Showroom, HR Team Wins OnCon Award
Orange, CA, November 15, 2024-M S International, Inc. (MSI), the supplier of flooring, countertops, wall tile, and ...
MSI Titan 18 HX A14V review
While the components inside are top-notch on paper, in the real world the Titan 18 HX makes very little sense. It's ...